The study evaluated sequencing of panitumumab and regorafenib in chemorefractory colorectal cancer, showing no difference in overall survival but superior response rates and disease control with panitumumab re-treatment. Adjustments in treatment sequence may optimize outcomes based on patient tolerance and previous treatment response.
Study
|
Randomized, open-label, multicenter, phase II study [PARERE, NCT04787341] |
| Chemorefractory metastatic colorectal cancer, RAS and BRAF wild-type patients who received 1st-line anti-EGFR regimen |
| Panitumumab followed by regorafenib (n=106) vs regorafenib followed by panitumumab (n=107)
|
Efficacy
|
ORR: 16% vs 2% (panitumumab first vs. regorafenib first) |
| mOS: 11.6 mos vs 11.7 mos (HR 1.13) |
| 1st-PFS: 4.2 mos vs 2.4 mos
|
Safety
|
Grade >=3 acneiform rash (19.2% vs 2.9%) |
| Grade >=3 hypertension (14% vs 1%) |
| Fatigue (9.8% vs 2.9%) |
| Hand-foot skin reaction (5.9% vs not reported)
|
Ann Oncol. Published online 2025 Oct 10
http://doi.org/10.1016/j.annonc.2025.10.002
Reviewed by Ulas D. Bayraktar, MD on Nov 17, 2025
